Alkermes (ALKS) PT Lowered to $45 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall St slides after strong jobs report bolsters hawkish Fed bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil slides on Friday, heads for weekly gain on US-Iran fight
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alkermes (ALKS) PT Lowered to $55 at Cowen
April 2, 2018 1:13 PM EDTCowen lowered its price target on Alkermes (NASDAQ: ALKS) to $55.00 (from $66.00) while maintaining an Outperform rating following the FDA'S RTF for the NDA for ALKS 5461.
"Amidst uncertainty over potential next steps which will play out over the coming months, out of... More
UPDATE: Evercore ISI Downgrades Alkermes (ALKS) to In Line
April 2, 2018 11:51 AM EDT(Updated - April 2, 2018 11:54 AM EDT)
(updated to add analyst comments)
Evercore ISI downgraded Alkermes (NASDAQ: ALKS) from Outperform to In Line with a price target of $50.00.
Analsyt Umer Raffat said the FDA delay of ALKS-5461 compresses the timelines further amidst several... More
Alkermes (ALKS) PT Lowered to $59 at Jefferies
April 2, 2018 10:48 AM EDTJefferies lowered its price target on Alkermes (NASDAQ: ALKS) to $59.00 (from $66.00) while maintaining a Hold rating.
... MorePre-Open Movers 04/02: (SLS) (MNOV) (CVLT) Higher; (ALKS) (SORL) (ITCI) Lower (more...)
April 2, 2018 9:21 AM EDTToday's Pre-Open Movers
SELLAS Life Sciences Group Inc., (Nasdaq: SLS) 44.9% HIGHER; announced positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin®) +/- nelipepimut-S (NeuVax) in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences.
MediciNova, Inc. (NASDAQ: MNOV) 27.2% HIGHER; announced that it will terminate the Phase 2 clinical trial of MN-001 (tipelukast) in NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) with... More
Intra-Cellular Therapies (ITCI) Trades Lower in Sympathy with Peer Alkermes (ALKS)
April 2, 2018 7:48 AM EDTIntra-Cellular Therapies (NASDAQ: ITCI) shares were in focus Monday after peer Alkermes (NASDAQ: ALKS) received a refuse to file letter from the FDA for ALKS 5461 for the adjunctive treatment of major depressive disorder.
Alkermes declined 18% and Intra-Cellular Therapies traded lower by as much as 9%.
... MoreAlkermes (ALKS) to Resume Traded at 7:30 am ET
April 2, 2018 7:09 AM EDTAlkermes (NASDAQ: ALKS) to Resume Traded at 7:30 am ET
... MoreAlkermes plc (ALKS) Says it Received Refusal to File Letter From FDA for ALKS 5461
April 2, 2018 7:00 AM EDTAlkermes plc (Nasdaq: ALKS) today announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies.
Upon its preliminary review, the FDA has taken the position that it is unable to complete a... More
